Advances in the Treatment of Colorectal Cancer with Peritoneal Metastases: A Focus on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
In stage IV colorectal cancer (CRC), peritoneal metastasis is associated with a poor prognosis. Hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery (CRS) is an effective treatment option that offers survival benefi...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ewha Womans University College of Medicine
2023-12-01
|
| Series: | The Ewha Medical Journal |
| Subjects: | |
| Online Access: | http://www.e-emj.org/archive/view_article?pid=emj-46-s1-27 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | In stage IV colorectal cancer (CRC), peritoneal metastasis is associated with a
poor prognosis. Hyperthermic intraperitoneal chemotherapy (HIPEC) after
cytoreductive surgery (CRS) is an effective treatment option that offers
survival benefits in patients with peritoneal metastatic CRC. For over the past
several decades, a multitude of studies have been conducted on CRS and HIPEC for
peritoneal metastatic diseases, and research in this area is ongoing. Proper
patient selection and a meticulous preoperative assessment are crucial for
achieving successful postoperative outcomes. The completeness of cytoreduction
and the surgical techniques employed are key factors in improving oncologic
outcomes following CRS and HIPEC. The role of HIPEC for both therapeutic and
prophylactic purposes is currently being evaluated in recent clinical trials.
This article reviews the fundamental principles of CRS combined with HIPEC and
discusses recent clinical trials concerning the treatment of CRS and HIPEC in
CRC patients with peritoneal carcinomatosis. |
|---|---|
| ISSN: | 2234-2591 |